Tilray Consolidates Canadian Cannabis Ops, Lifts FY27 EBITDA Guidance to $70M-$75M
TLRY is trading near its 52-week low of $2.485 (1.0% above the low).
Summary
Tilray is shutting cultivation and pre-roll production at its Foss facility in Fenwick, Ontario and moving it to Masson, Quebec and Cayuga, Ontario. The company expects about $10 million in annualized cost savings, with the full run rate starting in fiscal 2028. Masson's annual cultivation capacity rises from roughly 32.5 to 50 metric tonnes, and Tilray expects to reestablish EU-GMP certification there in calendar 2027, which matters for international medical sales. Management raised the low end of FY2027 adjusted EBITDA guidance to $70M-$75M from $68M-$75M. This follows a rough stretch: Q1 FY2027 missed on both lines with a $40.0M net loss, and last week Tilray said it was closing four U.S. breweries. Foss operations are expected to wrap by January 31, 2027.
At the time of this announcement, TLRY was trading at $2.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $373.9M. The 52-week trading range was $2.49 to $15.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.